GlassScriptPhysician profile
Milton Kahn
NPI 1750477006
$833.56
in general payments reported to CMS, 2019-2025
19 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $19.02 · 2021: $135 · 2022: $65.12 · 2023: $36.19 · 2024: $106 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $193.65 | 2019-2021 | |
| Alcon Vision LLC | $100.94 | 2025 | Rocklatan, Tryptyr, Eysuvis |
| Apellis Pharmaceuticals, INC. | $73.83 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $61.55 | 2025 | Xdemvy |
| Allergan, INC. | $56.07 | 2019-2021 | |
| Harrow Eye, LLC | $50.19 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $42.46 | 2021-2022 | |
| Astellas Pharma US INC | $37.44 | 2024 | Izervay |
| Bausch & Lomb Americas INC. | $29.22 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Genentech USA, INC. | $29.10 | 2019-2022 | |
| Abbvie INC. | $23.35 | 2022 | |
| Eyevance Pharmaceuticals LLC | $22.60 | 2019 | |
| Sight Sciences, INC. | $21.86 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Oyster Point Pharma, INC. | $19.56 | 2025 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $16.95 | 2024 | Eylea |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.90 | 2023 | Cequa |
| Alimera Sciences, INC. | $16.11 | 2021 | |
| Aerie Pharmaceuticals, INC. | $15.00 | 2021 | |
| Travere Therapeutics, INC. | $6.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.